Andrew Blauvelt, MD, MBA: Reviewing Upadacitinib Data in Atopic Dermatitis

October 9, 2026

Dr. Blauvelt discusses the safety and efficacy of upadacitinib in patients with moderate-to-severe atopic dermatitis (AD). In terms of efficacy, he references the Heads Up (NCT03738397) and the Level Up (NCT05601882) studies, which both showed superiority of upadacitinib vs dupilumab at both 15 mg and 30 mg doses. Dr. Blauvelt also added that upadacitinib has demonstrated a favorable safety profile in patients with AD and has been associated with low rates of major adverse cardiovascular events, death, thrombosis, and malignancy. Additionally, Dr. Blauvelt said upadacitinib benefits from convenience due to its oral administration vs injection.

Topics Covered:

The efficacy of upadacitinib in patients with moderate-to-severe atopic dermatitis
Trial data demonstrating the superiority of upadacitinib vs dupilumab
The safety profile of upadacitinib in patients with atopic dermatitis
The convenience of upadacitinib’s oral administration

MORE EXPERT PERSPECTIVES IN ATOPIC DERMATITIS

Andrew Mastro, MS, PA-C: Practical Prescribing and Patient Communication for Ruxolitinib in Atopic Dermatitis

Andrew Mastro, MS, PA-C, outlines the proper clinical application of ruxolitinib cream 1.5% as a noncontinuous topical treatment for mild-to-moderate atopic dermatitis in nonimmunocompromised patients

Melinda Gooderham, MD, MSc: Best Practices for JAK Inhibition in Atopic Dermatitis

Dr. Gooderham discusses using systemic Janus kinase (JAK) inhibitors like upadacitinib in patients with atopic dermatitis. She reviews appropriate indications for patient selection with JAK

Raj Chovatiya, MD, PhD, MSCI: Advancements in Topical Therapy for Atopic Dermatitis

Raj Chovatiya, MD, PhD, discusses advances in topical atopic dermatitis treatment, including ruxolitinib, rapid itch relief, and treatment of difficult areas.

David Seiter, FNP-C: Rapid Relief for Atopic Dermatitis Flares

David Seiter, FNP-C, shares a patient success story involving a teenage patient with severe atopic dermatitis that achieved complete skin clearance within one week after

Christopher Bunick, MD, PhD: Rapid Itch Relief with Upadacitinib vs. Dupilumab in Atopic Dermatitis

Christopher Bunick, MD, PhD, an associate professor of dermatology at Yale School of Medicine in New Haven, Connecticut, discusses a poster presentation comparing the itch

George Han, MD, PhD: Advancing Atopic Dermatitis Care: Early Use of Topical JAK Inhibitors

George Han, MD, PhD, discusses the evolving treatment strategies for patients with atopic dermatitis.

Kara Mudd DMSc, PA-C: Use of Ruxolitinib in Pediatric Patients with Atopic Dermatitis

Kara Mudd reviews findings from the Phase 3 TRuE-AD3 study evaluating topical ruxolitinib in children aged 2 to <12 years with atopic dermatitis. The discussion

Mona Shahriari, MD: Removal of Black Box Warnings Change Considerations for Hormonal Therapy in Atopic Dermatitis

Dr. Shahriari reviews the FDA’s decision to remove certain “black box” warnings for hormone replacement therapy (HRT) and discusses how this shift may influence treatment

Emma Guttman-Yassky, MD: Evaluating Long-term Efficacy of Upadacitinib in Patients with Atopic Dermatitis

Dr. Johann Gudjonsson discusses how spesolimab may reduce low-grade inflammation between flares in patients with generalized pustular psoriasis (GPP). Topics Covered: Subclinical inflammation in GPP

Lisa Swanson, MD: Topical Therapies for the Treatment of Atopic Dermatitis

Dr. Lisa Swanson highlights three effective nonsteroidal topical therapies for managing atopic dermatitis in both pediatric and adult patients. Topics Covered: Nonsteroidal topical options for

Raj Chovatiya, MD, PhD: Maintaining Optimal Treatment Targets with Upadacitinib for Patients with Atopic Dermatitis

Dr. Raj Chovatiya presents long-term data on upadacitinib’s ability to maintain skin clearance and itch relief in atopic dermatitis patients over 140 weeks. Topics Covered:

Diego Ruiz Dasilva, MD, FAAD: Investigating Combination Topical Ruxolitinib and Systemic Therapies for Atopic Dermatitis

Dr. Diego Ruiz Dasilva reviews real-world data showing the safety and efficacy of combining topical ruxolitinib with systemic therapies in atopic dermatitis care. Topics Covered:

Andrew Mastro, MS, PA-C: Managing the Psychosocial and Occupational Burden of Chronic Hand Eczema

Andrew Mastro, MS, PA-C, addresses the psychosocial impact of chronic hand eczema and highlights emerging treatments like biologics and JAK inhibitors. Topics Covered: Quality of

Andrew Mastro, MS, PA-C: Providing Effective Treatment for the Head-and-neck Area in Patients with Atopic Dermatitis

Andrew Mastro, MS, PA-C, addresses the psychosocial impact of chronic hand eczema and highlights emerging treatments like biologics and JAK inhibitors. Topics Covered: Quality of

Naiem T. Issa, MD, PhD: Mitigating Economic Impacts of Atopic Dermatitis through Effective Treatment

Dr. Naiem Issa shares real-world evidence showing how ruxolitinib cream may reduce treatment costs and productivity loss in patients with atopic dermatitis. Topics Covered: Economic

Diego Ruiz Dasilva, MD, FAAD: Achievement of Optimal Treatment Targets with Oral JAK Inhibition in Elderly Patients with Atopic Dermatitis

Dr. Diego Ruiz Dasilva highlights real-world data showing oral JAK inhibitors can safely and effectively achieve treatment targets in elderly patients with AD. Topics Covered:

Lisa Swanson, MD: Insights on Maximum-use of Ruxolitinib Cream in Pediatric Patients with Atopic Dermatitis

Dr. Lisa Swanson shares insights on maximum-use data for ruxolitinib cream in children ages 2–11 with atopic dermatitis, highlighting safety and efficacy. Topics Covered: Ruxolitinib

Michael Cameron, MD, FAAD: Improving Itch and Quality of Life in Patients with Atopic Dermatitis

Dr. Michael Cameron discusses 52-week results showing rapid and lasting improvements in itch and quality of life with upadacitinib plus topical steroids. Topics Covered: Combination

James Song, MD: Personalizing Treatment for Atopic Dermatitis

Dr. James Song highlights the need for personalized approaches in atopic dermatitis care to predict treatment response and reduce trial-and-error prescribing. Topics Covered: Personalization in

James Song, MD, FAAD: Checking in on Long-term Safety Data on JAK Inhibitors for Atopic Dermatitis

Dr. James Song reviews the latest long-term safety data on topical and oral JAK inhibitors for managing atopic dermatitis**.** Topics Covered: Long-term safety of JAK

JCAD Archives